References
- Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23:209–213.
- Lavatelli F, Merlini G. Advances in proteomic study of cardiac amyloidosis: progress and potential. Expert Rev Proteomics. Oct 2016;19:1–11. [Epub ahead of print].
- Nuvolone M, Merlini G. Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant. 2016:pii: gfw305. [Epub ahead of print].
- Dogan A. Amyloidosis: insights from proteomics. Annu Rev Pathol. 2017;12:277–304.
- Lavatelli F, Di Fonzo A, Palladini G, et al. Systemic amyloidoses and proteomics: the state of the art. Eupa Open Proteomics. 2016;11:4–10.
- Picken MM. Proteomics and mass spectrometry in the diagnosis of renal amyloidosis. Clin Kidney J. 2015;8:665–672.
- Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114:4957–4959.
- Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood. 2012;119:1844–1847.
- Vrana JA, Theis JD, Dasari S, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica. 2014;99:1239–1247.
- Gilbertson JA, Theis JD, Vrana JA, et al. A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. J Clin Pathol. 2015;68:314–317.
- Fernández De Larrea C, Verga L, Morbini P, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood. 2015;125:2239–2244.
- Obici L, Nuvolone M, Merlini G. Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney. Kidney Int. 2016;90:479–481.
- Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121:5124–5130.
- Kourelis TV, Dasari S, Theis JD, et al. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 2017;129:299–306.
- Brambilla F, Lavatelli F, Di Silvestre D, et al. Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. J Proteome Res. 2013;12:5642–5655.
- Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med. 2017;281:337–347.
- Marcoux J, Mangione PP, Porcari R, et al. A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Mol Med. 2015;7:1337–1349.
- Dasari S, Theis JD, Vrana JA, et al. Clinical proteome informatics workbench detects pathogenic mutations in hereditary amyloidoses. J Proteome Res. 2014;13(5):2352–2358.
- Barnidge DR, Dispenzieri A, Merlini G, et al. Monitoring free light chains in serum using mass spectrometry. Clin Chem Lab Med. 2016;54:1073–1083.
- Botz CM, Barnidge DR, Murray DL, et al. Detecting monoclonal light chains in urine: microLC-ESI-Q-TOF mass spectrometry compared to immunofixation electrophoresis. Br J Haematol. 2014;167:437–438.
- Mills JR, Kohlhagen MC, Dasari S, et al. Comprehensive assessment of m-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016;62:1334–1344.